Patents Assigned to CVI Pharmaceuticals Limited
  • Polymorphs of Crystalline Forms of 3,10-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-9-yl 3-fluorobenzenesulfonate and Salts Thereof
    Publication number: 20230279002
    Abstract: Crystalline salts of compounds, methods of making the same, and methods of treatment of dyslipidemia including administration of the crystalline salts, are provided.
    Type: Application
    Filed: March 1, 2023
    Publication date: September 7, 2023
    Applicant: CVI Pharmaceuticals Limited
    Inventors: Shenyi Shi, Feng Wang, Jingwen Liu, Jian Yang
  • Compounds and compositions for reducing lipid levels
    Patent number: 8815900
    Abstract: Compositions comprising extracts or isolated or purified compounds from plants of the genus Corydalis provide prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Corydalis compounds and their derivatives of natural and synthetic origins lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression and activate AMP-activated protein kinase. Specific stereoisomers of Corydalis compounds with lipid lowering activity include 14R-(+)-corypalmine, 14R,13S-(+)-corydaline, 14R-(+)-tetrahydropalmatin, (+)-corlumidin, d-(+)-bicuculline, and (+)-egenine.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: August 26, 2014
    Assignee: CVI Pharmaceuticals Limited
    Inventors: Haiyan Liu, Junbo Wang, Rui Zhang, Nicholas Cairns, Jingwen Liu
  • Compounds, compositions and methods for reducing lipid levels
    Patent number: 8710071
    Abstract: The present technology relates to compounds of Formulas (V) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: April 29, 2014
    Assignee: CVI Pharmaceuticals Limited
    Inventors: Haiyan Liu, Gaoping Li, Junbo Wang, Jingwen Liu
  • Compounds and compositions for reducing lipid levels
    Patent number: 8003795
    Abstract: Compositions comprising extracts or isolated or purified compounds from plants of the genus Corydalis provide prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Corydalis compounds and their derivatives of natural and synthetic origins lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression and activate AMP-activated protein kinase. Specific stereoisomers of Corydalis compounds with lipid lowering activity include 14R-(+)-corypalmine, 14R,13S-(+)-corydaline, 14R-(+)-tetrahydropalmatin, (+)-corlumidin, d-(+)-bicuculline, and (+)-egenine.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: August 23, 2011
    Assignee: CVI Pharmaceuticals Limited
    Inventors: Haiyan Liu, Junbo Wang, Rui Zhang, Nicholas Cairns, Jingwen Liu